GSK plc
NYSEGSK plc saw short interest surge 48.6% over the past week, bringing total shares short to 16.06 million as of March 31st. Days to cover climbed to 3.59, up from 2.44 in the prior settlement period. The British pharmaceutical giant has attracted renewed bearish attention despite an 8.3% price gain over the past month. Shares closed at $56.12 on April 21st, down 5.2% over the past week. Cost to borrow remains modest at 0.59% APR, down 10.6% week-over-week. Utilization stands at 55.4%, roughly half the 52-week high of 94.4% reached earlier this year. This suggests ample shares remain available for shorting. The sharp weekly increase follows a choppy pattern in GSK's short interest. Total shares short had declined 9.4% over the past month, dropping from 17.7 million in late January to a low of 10.8 million in late February before the recent reversal. Options sentiment remains neutral, with the put/call ratio at 0.55 — slightly below the 20-day average of 0.56. GSK reports earnings April 29th. The renewed short buildup comes as the pharmaceuticals sector faces continued scrutiny over pricing and pipeline concerns. Whether bears can profit will depend on GSK's upcoming quarterly results and any pipeline updates. This is not financial advice. Data may contain errors.
Short Sellers Pile Into GSK
GSK plc saw short interest surge 48.6% over the past week, bringing total shares short to 16.06 million as of March 31st. Days to cover climbed to 3.59, up from 2.44 in the prior settlement period. The British pharmaceutical giant has attracted renewed bearish attention despite an 8.3% price gain over the past month. Shares closed at $56.12 on April 21st, down 5.2% over the past week. Cost to borrow remains modest at 0.59% APR, down 10.6% week-over-week. Utilization stands at 55.4%, roughly half the 52-week high of 94.4% reached earlier this year. This suggests ample shares remain available for shorting. The sharp weekly increase follows a choppy pattern in GSK's short interest. Total shares short had declined 9.4% over the past month, dropping from 17.7 million in late January to a low of 10.8 million in late February before the recent reversal. Options sentiment remains neutral, with the put/call ratio at 0.55 — slightly below the 20-day average of 0.56. GSK reports earnings April 29th. The renewed short buildup comes as the pharmaceuticals sector faces continued scrutiny over pricing and pipeline concerns. Whether bears can profit will depend on GSK's upcoming quarterly results and any pipeline updates. This is not financial advice. Data may contain errors.
Snapshot as of 7 May 2026
GSK heads into its May 6 Q1 results carrying sharply higher short positioning — yet the borrow market tells a more nuanced story than the headline shorts figure suggests. Short interest on the NYSE-listed ADR has…
GSK delivered a clean Q1 beat on April 29 and reaffirmed full-year guidance. The market sold the news hard anyway, dropping the stock 5.6% on the day and 7.7% across the week to $51.40. The earnings numbers were…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GSK — free to start on ORTEX.
Sign up for free →Open GSK on ORTEX